Market Newsdesk

HUNTINGTON, W. Va., Jan. 11, 2021 (GLOBE NEWSWIRE) — Life is slow and predictable in RiverCreek, Minnesota, a small town nestled in the suburban sprawl between Minneapolis and St. Paul. High schooler Cory Dubois longs for the moment he can swap starlit skies for city lights and his hockey skates for a scalpel. However, the arrival of Southern beauty Tara Rose shakes things up for Cory and the rest of RiverCreek’s residents.

In his new contemporary romance novel, “Escaping River Creek,” author Jason Blayne explores the nuances of first love and the adolescent choices that shape life’s trajectory. Passion immediately ignites between Cory and Tara, leading both to intense emotions and harsh conflict. The relationship inspires Cory to become more motivated and self-assured and improves his performance on the ice, his growth and athletic prowess rewarded when he receives a scholarship to a prominent university in Ohio.

Tara becomes angry when Cory considers a different school and threatens to alter the plan they had created for their lives. A bitter battle between the two sweethearts results in an accidental death of a friend and the murder of another, a ripple effect that rattles RiverCreek and threatens their happily-ever-after.

Through “Escaping RiverCreek,” Blayne reminds readers that actions have powerful consequences and to be mindful of the choices they are making, especially in the heat of a moment or under love’s dizzying spell. Despite Cory and Tara’s dreams taking a difficult and unexpected turn, the book demonstrates that while life gets tough, love is always there to see people through.

“’Escaping RiverCreek’ is for anyone who loves second-chance romances and would like reminisce and reflect on their past,” said Blayne. “The book offers an opportunity to look back and remember how it felt to go through tough times and almost make their dreams come true only to change course and navigate an uncharted path.”

“Escaping RiverCreek”
By Jason Blayne
ISBN: 9781480899025 (softcover); 9781480899032 (electronic)
Available from Amazon, Barnes & Noble and Archway Publishing

About the author
Author Jason Blayne writes romance novels and the occasional thriller for adults and young adults alike. He is known for bringing a surprising twist to his stories, breaking from the traditional and weaving in mayhem and anarchy to create exciting adventures for his readers. His previous books include the “Shadow Wolves” trilogy and the “Twisted Saga” trilogy as well as contemporary romance novels “A Heart Split for Two” and “45 Days,” and a Western-style romance, “Cherry Skies.” He currently lives in Huntington, West Virginia, where he was born and raised. To learn more about Blayne, visit his Amazon Author Page (Jason S. Blayne) or connect with him on Twitter (@JasonBlayne).

Simon & Schuster, a company with nearly ninety years of publishing experience, has teamed up with Author Solutions, LLC, the worldwide leader in self-publishing, to create Archway Publishing. With unique resources to support books of all kind, Archway Publishing offers a specialized approach to help every author reach his or her desired audience. For more information, visit www.archwaypublishing.com or call 888-242-5904.

Attachment

• 816776HiRes

LOS ANGELES, Jan. 11, 2021 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Interface, Inc. (NASDAQ: TILE)
Class Period:   March 2, 2018 – September 28, 2020
Lead Plaintiff Deadline: January 11, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (2) consequently, Interface, inter alia, reported artificially inflated income and EPS in 2015 and 2016; (3) Interface and certain of its employees were under investigation by the SEC with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC’s investigation, and downplayed the true scope of the Company’s wrongdoing and liability with respect to the SEC investigation; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Alibaba Group Holding Limited (NYSE: BABA)
Class Period: July 20, 2020 – November 3, 2020
Lead Plaintiff Deadline:   January 12, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Ant Group did not meet listing qualifications or disclosure requirements for certain material matters; (2) that certain impending changes in the Fintech regulatory environment would impact Ant Group’s business; (3) that, as a result of the foregoing, Ant Group’s IPO was reasonably likely to be suspended; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Biogen, Inc. (NASDAQ: BIIB)
Class Period: October 22, 2019 – November 6, 2020
Lead Plaintiff Deadline:   January 12, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

LOS ANGELES, Jan. 11, 2021 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

JOYY Inc. (NASDAQ: YY)
Class Period:   April 28, 2016 – November 18, 2020
Lead Plaintiff Deadline: January 19, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) the majority of users at any given time were bots; (3) the Company utilized these bots to effect a roundtripping scheme that manufactured the false appearance of revenues; (4) the Company overstated its cash reserves; (5) the Company’s acquisition of Bigo was largely contrived to benefit corporate insiders; and (6) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

K12 Inc. (NYSE: LRN)
Class Period: April 27, 2020 – September 18, 2020
Lead Plaintiff Deadline:   January 19, 2021

Shareholders with $100,000 losses or more are encouraged to contact the firm

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) K12 lacked the technological capabilities, infrastructure, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (2) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer systems; (3) K12 was unable to provide the necessary levels of administrative support and training to teachers, students, and parents; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Fortress Biotech, Inc. (NASDAQ: FBIO)
Class Period: December 11, 2019 – October 9, 2020
Lead Plaintiff Deadline:   January 26, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) IV Tramadol was not safe for the intended patient population; (2) as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

TUCSON, Ariz., Jan. 11, 2021 (GLOBE NEWSWIRE) — Human reasoning has its limitations and constraints. Often, people experience shortsightedness when it comes to the bigger picture of God’s plan, which in turn evokes worry, skepticism and judgment. In her new novel, “Everything Good,” author Carolyn A. Spangler explores what it truly means to live in faith and trust in the Lord.                                   

Set in a quiet, idyllic town near Lake Michigan, “Everything Good” continues the stories of Emily, Franklin, Katie and Tom, who are each facing considerable changes. Emily, an English teacher, contends with her conflicting feelings about remarriage while her beau, Franklin, balances the bittersweet emotions following his promotion to assistant principal. Grappling with an unexpected loss and insecurity over her relationship, Emily’s daughter, Katie, struggles for direction while her brother, Tom, offers spiritual guidance to patients in the hospital as he waits for his new life to begin.

As the four work through their personal matters, a new problem suddenly arises when Franklin discovers a school custodian’s body in his classroom closet. Each character holds a vital clue to what happened, and together, they work to unravel the mystery behind the murder while they learn important lessons about love, compassion and, most importantly, faith.

Through her writing, Spangler seeks to show readers the core of Christianity, differentiate between the actions of people and the intentions of Christ, and shed light on important issues concerning believers. Tom’s ministry in the hospital brings him face to face with nonbelievers who have experienced callousness from Christians, demonstrating the reasons many people may feel reluctant or disenchanted toward religion. Katie also embarks on an emotional spiritual journey, and her tough questions surrounding faith may feel familiar to readers who have shared her position.

“My goal is to present a more authentic perspective on what Christianity is all about and illustrate that God has a plan for all of our lives,” said Spangler. “I also want to emphasize why it’s important for Christians to walk the walk and make it clear that their actions can impact others’ perception of Jesus.”

Weaving warmth, tenderness and romance with a suspenseful murder mystery, “Everything Good” reminds readers that God offers compassion, grace and peace amid life’s storms.

“Everything Good”
By Carolyn A. Spangler
ISBN: 9781462413157 (softcover); 9781462413140 (electronic)
Available from Amazon, Barnes & Noble and other retailers

About the author
Carolyn A. Spangler received degrees from New York University and Western Michigan University. She taught high school English, along with creative writing, for 25 years and during that time developed a strong desire to become an author. Writing is her passion along, and she enjoys using her books to draw Christians attention to relevant issues. Spangler has written two other novels: “Never Alone” (2005) and “Joy Comes in the Morning” (2014). She currently lives in Tucson, Arizona, where she is working on her fourth book. 

Inspiring Voices is dedicated to helping authors share their words of hope, faith and inspiration with the world. Inspiring Voices allows authors to publish inspirational and spiritual books without respect to their specific doctrine, denomination or political point-of-view. For more information on publishing with Inspiring Voices, log on to inspiringvoices.com or call 866-697-5313.

Attachment

• 818329HiRes

Portland, Jan. 11, 2021 (GLOBE NEWSWIRE) — Scott’s Cheap Flights, a service that tracks airfare prices and alerts its 2 million members to exceptional airfare deals, recently surveyed more than 5,800 Scott’s Cheap Flights members and dove deep into our own data to look at how consumers are planning to travel in 2021-including how the coronavirus affected their previous plans and the trips they expect to take this year.

Some noteworthy findings from our State of Cheap Flights report include:

• No surprise, 2020 was not a good year for travelers: In our 2020 report, only 4% of respondents predicted they would not take any international trips. But the coronavirus upended those predictions. As it turns out, the majority (68%) of all respondents didn’t end up traveling internationally in 2020.
• There were a lot of canceled trips, but it wasn’t a total loss for most people: The vast majority (72%) of respondents had at least one 2020 flight canceled due to Covid-19.
• Not all travel came to an end, though—and the flying experience was better than many expected: In fact, 45% of respondents have taken a trip by plane since the pandemic began. More than half (80%) of respondents gave the experience four or five (out of five) stars.
• We’re still in the Golden Age of Cheap Flights, and still will be after the pandemic: The pandemic certainly did cause prices to drop, but it didn’t do so in the way many expected. Many of the prices we’ve seen during the pandemic—like $230 to Europe or $300 to South America—aren’t that much lower than fares we’ve seen in the past. Instead, the pandemic resulted in a big increase in rare, valuable deals (namely, mistake fares, when an airline accidentally sells tickets at a huge discount) and deals for peak summer and holiday travel, which are normally the most expensive times to travel.

For the full State of Cheap Flights report please click here.

About Scott’s Cheap Flights

Since 2015,

Scott’s Cheap Flights

has helped members around the world make their travel dreams come true. We combine sophisticated software and human Flight Experts to discover flight deals and mistake fares up to 90% off and email them to our 2+ million members.

Unlike fully automated fare alerts services, every deal alert we send to members has passed a rigorous quality evaluation by our team to ensure it’s worth members’ hard-earned money and limited travel time. Our members save $550 per ticket on average, and every month we receive over 1,000 testimonials from happy members who’ve scored a great deal on a flight thanks to our email.

ERIE, Kan., Jan. 11, 2021 (GLOBE NEWSWIRE) — Rhonda Kane has lived an ordinary life, one filled with events and experiences that onlookers might describe as universal or unnoteworthy. However, as she explains in her book, “Ordinary Day. Remarkable God.,” even the most habitual moments of her day-to-day life are made extraordinary and profound by her close relationship with the Lord.

Warm, honest and vulnerable, “Ordinary Day. Remarkable God.” resembles an intimate conversation with a lifelong friend. Kane pulls back the curtains and shares stories of family, career, ministry, faith and introspection along with reflections and prayers that God has bestowed on her heart. From divorcing young, blending families, adopting children and caring for a mother with Alzheimer’s disease to working as a nurse, leading a high school youth group, managing a free store ministry and growing as a woman of God, she adeptly captures the ebbs and flows of life while ruminating on all that she has gained spiritually from both the blissful and heavy-hearted moments.

Through personal vignettes and relatable musings about faith, Kane demonstrates that, regardless of what life brings, believers are never left stranded to journey through the peaks and valleys alone. Her stories draw attention to the omniscience and omnipresence of God, illuminating how His love, compassion, grace and peace make every day exceptional. With her book, she seeks to inspire others to slow down and focus on growing close to Him, listening for His voice and feeling His nearness.

“God is not only present but remarkable in our ordinary lives,” said Kane. “Every day holds opportunities to stop and seek Him, but we must be intentional and determined, or we risk missing those moments. We don’t have to be perfect to achieve this; He already is.”

“Rhonda Kane has demonstrated that she has an intimate and growing relationship with the Father, and I can say with confidence that reading this book will draw you closer to Him as well,” wrote Pastor Kevin Bayless of Galesburg Christian Church in the book’s foreword. “She looks at God’s creation with wonder and awe and her writing will guide your heart to see God’s beauty, His control and His love for mankind.”

An uplifting and comforting reminder of God’s magnificent glory, “Ordinary Day. Remarkable God.,” encourages readers to allow Him to walk beside them as they navigate the winding roads of life.

“Ordinary Day. Remarkable God.”
By Rhonda Kane
ISBN: 9781664209046 (softcover); 9781664209039 (electronic)
Available from Amazon, Barnes & Noble and WestBow Press

About the author
Rhonda Kane lives in the small town of Erie, KS, with her husband of 20 years. They have eight children collectively and seventeen grandchildren, a blended family of his, hers and the grace of someone else. Her love of writing began with creating prayer journals, writing her husband’s communion meditations and posting short stories on social media. She found the most joy in writing about what God has taught her through the figurative mountains and valleys of her life. Through times of wandering, raising children, enjoying grandchildren, working as a nurse for 37 years, helping care for a mother with Alzheimer’s, leading a high school youth group for eleven years, and founding and managing a free store, God has presented stories and moments of learning that only He could’ve orchestrated. For more of Kane’s musings, please visit ordinarydayremarkablegod.com.

WestBow Press is a strategic supported self-publishing alliance between HarperCollins Christian Publishing and Author Solutions, LLC — the world leader in supported self-publishing. Titles published through WestBow Press are evaluated for sales potential and considered for publication through Thomas Nelson and Zondervan.  For more information, visit www.westbowpress.com or call (866)-928-1240.

Attachment

• 809445HiRes

Highland, CA, Jan. 11, 2021 (GLOBE NEWSWIRE) — San Manuel Casino is proud to announce that it is among the first entertainment venues in the world to become Sharecare Health Security VERIFIED® with Forbes Travel Guide. The comprehensive facility verification helps ensure that guests and travel planners can visit with confidence at properties that have appropriate health safety procedures in place.

This verification comes with an easily identifiable “seal of approval” – the Sharecare VERIFIED® with Forbes Travel Guide badge – based on the property’s compliance with expert-validated best practices that minimize the risk and impact of COVID-19 and potential future public health events.

“This recognition is a testament to the Tribe’s values and unwavering desire to put people first, as well as our team members’ relentless efforts and dedication to safety,” said General Manager Peter Arceo. “During the closure of the casino, we worked tirelessly to create one of the most robust safety plans in the country. We trained all our employees under the guidance of medical experts, introduced new technology to minimize touchpoints, and made rigorous modifications throughout our entire property.”

Developed by Forbes Travel Guide, the global authority on genuine Five-Star service, and digital health industry leader Sharecare, the comprehensive verification covers more than 360 standards across health and hygiene protocols, cleaning products and procedures, ventilation, physical distancing, the guest experience, and health safety communication with guests and employees. Properties are required to verify their health protocols on an ongoing basis to ensure continued compliance with the most up-to-date global health standards.

“The pandemic has made it clear that venues must, first and foremost, assure guests of their safety,” said Filip Boyen, CEO of Forbes Travel Guide. “By becoming VERIFIED®, San Manuel Casino has demonstrated its commitment to creating a culture of accountability and following global best practices to heighten health security, certified by a third party.”

For a complete list of hotels and resorts that currently are Sharecare Health Security VERIFIED® with Forbes Travel Guide, please visit www.forbestravelguide.com/verified.

About San Manuel Casino

San Manuel Casino is Southern California’s one-stop destination for entertainment and fun, located just 60 minutes from downtown Los Angeles and a short drive from LA-Ontario International Airport. San Manuel Casino guests enjoy the most slots on the West Coast, Vegas-style blackjack, high-limit gaming, live entertainment, sumptuous dining and a generous player’s reward program. Since 1986, players have received over $2 billion in cash, prizes and giveaways, making any visit to San Manuel an exciting and memorable experience. For more information on San Manuel Casino, visit www.SanManuel.com and follow us on Twitter, Instagram and Facebook.

About Forbes Travel Guide

Forbes Travel Guide is the only independent, global rating system for luxury hotels, restaurants and spas. Started as Mobil Travel Guide in 1958, the company created the first Five-Star rating system in the United States. Today, Forbes Travel Guide’s incognito inspectors travel the world, evaluating properties based on up to 900 rigorous, objective standards. Forbes Travel Guide also supports the hospitality industry and other service-oriented businesses such as luxury residential, healthcare and private clubs with bespoke training solutions, evaluation services and the creation of custom service standards. For more information, please visit partner.forbestravelguide.com.

About Sharecare

Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.

# # #

Attachment

• Building_SMC

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

The presentation is now available “on-demand” by visiting https://hcwevents.com/bioconnect/#

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Safe Harbor / Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company’s clinical trials, including without limitation the mOM and ICC clinical trial programs, our determination whether to continue the ICC clinical trial program or to focus on other alternative indications, and timely monitoring and treatment of patients in the global Phase 3 mOM clinical trial and the impact of the COVID-19 pandemic on the completion of our clinical trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; approval of Individual Funding Requests for reimbursement of the CHEMOSAT product; the impact, if any, of ZE reimbursement on potential CHEMOSAT product use and sales in Germany; clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK; the Company’s ability to successfully commercialize the HEPZATO KIT/CHEMOSAT system and the potential of the HEPZATO KIT/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver; our ability to obtain reimbursement for the CHEMOSAT system in various markets; approval of the current or future HEPZATO KIT/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets; actions by the FDA or foreign regulatory agencies; the Company’s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same; uncertainties relating to the timing and results of research and development projects; and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact:

Delcath Investor Relations

Email: [email protected]

Hayden IR

James Carbonara 
(646)-755-7412 
[email protected]